株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

呼吸器感染症診断の世界市場 - 新型コロナウイルス感染症 (COVID-19) の影響を含む予測・分析:2020年~2024年

Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with Covid-19 Impact & Forecasting/analysis, and Executive and Consultant Guides 2020-2024

発行 Howe Sound Research 商品コード 933295
出版日 ページ情報 英文 308 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.72円で換算しております。
呼吸器感染症診断の世界市場 - 新型コロナウイルス感染症 (COVID-19) の影響を含む予測・分析:2020年~2024年 Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with Covid-19 Impact & Forecasting/analysis, and Executive and Consultant Guides 2020-2024
出版日: 2020年05月01日 ページ情報: 英文 308 Pages
担当者のコメント
COVID-19の感染が未だ続く世界事情の中、呼吸器感染症診断に着目した最新の調査レポートが、Howe Sound Research社よりリリースされました。、各主要プレーヤのプロフィール及び最新のパイプライン分析他、国別の市場情トレンド、成長促進要因、抑制要因 、計測と自動化 、診断技術の最新の展開、という観点から当レポートは分析しております。ご希望がありましたら、抜粋サンプルを用意していますので、お気軽にお問い合わせください。
概要

コロナウイルス感染症 (COVID-19) は、呼吸器感染症のポイントオブケア (POC) 検査の市場を開拓しました。現在、市場シェアの競争が本格的に始まっています。医療施設、クリニック、診療所などで、大規模な新しい市場が開かれています。

当レポートでは、世界の呼吸器感染症診断市場について調査分析し、市場の概要、戦略、動向、予測について、体系的な情報を提供しています。

目次

第1章 イントロダクションと市場の定義

  • 呼吸器感染症とは
  • 診断と治療の役割
  • 市場の定義
  • 調査手法
  • 臨床検査における支出の見通し

第2章 市場概要

  • 動的市場の企業
  • 呼吸器感染症
  • 診断 - 役割の変化

第3章 市場動向

  • 成長促進要因
  • 成長抑制要因
  • 計装と自動化
  • 診断技術の発展

第4章 呼吸器感染症診断の最近の動向

  • 最近の動向
    • Mammoth Biosciences
    • Genetic Signatures
    • Qiagen
    • Lumos Diagnostics
    • Fusion Genomics、など

第5章 主要企業のプロファイル

  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akkoni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Atlas Genetics
  • Aus Diagnostics
  • BD Diagnostics
  • Biocartis
  • BioFire Diagnostics
  • bioMerieux
  • Bio-Rad Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Co-Diagnostics
  • Cue Health
  • Curetis
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin
  • Expedeon
  • Fusion Genomics.
  • GenePOC Diagnostics
  • Genetic Signatures
  • GenMark Dx
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexigene
  • Luminex
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Oxford Nanopore
  • Panagene
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • T2 Biosystems
  • Thermo Fisher
  • Veradus Labs
  • Veramarx

第6章 世界の呼吸器感染症診断市場

  • 世界市場の概要:国別
  • 世界市場:技術別 - 概要
  • 世界市場:プレックス別 - 概要
  • 世界市場:場所別 - 概要

第7章 世界の呼吸器感染症診断市場:技術別

  • 微生物学
  • PCR
  • NGS
  • イムノアッセイ
  • その他

第8章 世界の呼吸器感染症診断市場:プレックス別

  • シングルプレックス
  • デュプレックス
  • トリプレックス
  • マルチプレックス技術

第9章 世界の呼吸器感染症診断市場:場所別

  • 病院ラボ
  • 外来ラボ
  • POC
  • その他
図表

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2020 ($million)
  • Table 2 Market Players by Type
  • Table 3 Bacterial Causes of Pneumonia
  • Table 4 List of Influenza Pandemics
  • Table 5 Viral Infections of the Respiratory Tract
  • Table 6 Fungal Infections of the Respiratory Tract
  • Table 7 Five Factors Driving Growth
  • Table 8 Three Factors Limiting Growth
  • Table 9 Key Diagnostic Laboratory Technology Trends
  • Table 10 - Global Market by Region
  • Table 11 Global Market by Technology
  • Table 12 Global Market by Plex
  • Table 13 Global Market by Place
  • Table 14 Microbiology by Country
  • Table 15 PCR by Country
  • Table 16 NGS by Country
  • Table 17 Immunoassay by Country
  • Table 18 Other by Country
  • Table 19 Single Plex by Country
  • Table 20 Duplex by Country
  • Table 21 Triplex by Country
  • Table 22 Multiplex by Country
  • Table 23 Hospital Lab by Country
  • Table 24 Outpatient Lab by Country
  • Table 25 POC by Country
  • Table 26 Other by Country
  • Table 27 2020 Laboratory Fee Schedule

Table of Figures

  • Figure 1 Upper vs. Lower Respiratory Tract
  • Figure 2 The LRI Mortality Rate Globally
  • Figure 3 Global Pandemic Pathogen Status
  • Figure 4 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 5 The BioFire Respiratory Panel
  • Figure 6 Pneumonia
  • Figure 7 Bacterial Infections of the Respiratory Tract
  • Figure 8 The Development Cycle of Tuberculosis
  • Figure 9 A Flu Epidemic in Europe - Historical Pattern
  • Figure 14 The Multiplex Paradigm Shift
  • Figure 11 Percentage of World Population Over 65
  • Figure 12 2019 Global Market Density Chart
  • Figure 13 Global Market by Technology - 2019 vs. 2024
  • Figure 14 Global Market by Technology 2019
  • Figure 15 Global Market by Technology 2024
  • Figure 16 Technology Share by Year
  • Figure 17 Plex - 2019 vs. 2024
  • Figure 18 Plex Market 2019
  • Figure 19 Plex Market 2024
  • Figure 20 Plex Share by Year
  • Figure 21 Place - 2019 vs. 2024
  • Figure 22 Place Market 2019
  • Figure 23 Place Market 2024
  • Figure 24 Place Share by Year
  • Figure 25 Microbiology Growth
  • Figure 26 PCR Diagnostics Growth
  • Figure 27 NGS Growth
  • Figure 28 Immunoassay Growth
  • Figure 29 Other Growth
  • Figure 30 Single Plex Growth
  • Figure 31 Duplex Growth
  • Figure 32 Triplex Growth
  • Figure 33 Multiplex Growth
  • Figure 34 Hospital Lab Growth
  • Figure 35 Outpatient Lab Growth
  • Figure 36 POC Growth
  • Figure 37 Other Growth
目次

OVERVIEW:

COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. In health facilities, clinics, physicians' offices and elsewhere. And lets not forget the screening market, not just for COVID, but for the rest of the 20 something respiratory pathogens as well. Multiplex vs single plex? Explore the rapidly changing market as competitors jockey for position in new markets that are not yet well understood.

New technology is forever changing the diagnosis of respiratory infections. Shrinking time to result is opening up markets multiple times the size of current microbiology based practice. Diagnosis has already moved into the Emergency Room. It is now moving to the Physician's Office Lab. Could the Home be next?

The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress. The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory, already the largest infectious disease category could multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this in depth report.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Respiratory Infections Diagnostic Market - Strategic Situation Analysis and Impact of COVID-19.

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What are Respiratory Infections?
  • 1.2 The Role of Diagnosis & Treatment
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 A Spending Perspective on Clinical Laboratory Testing
    • 1.5.1 An Historical Look at Clinical Testing

2. Market Overview

  • 2.1 Players in a Dynamic Market
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Instrumentation Supplier
    • 2.1.4 Distributor and Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab
    • 2.1.8 Physician Office Labs
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Respiratory Infections
    • 2.2.1 Upper vs. Lower - Marketing Implications
    • 2.2.2 Understanding the Role of Pneumonia
    • 2.2.3 Bacterial Infections
      • 2.2.3.1 Streptococcal Infections
      • 2.2.3.2 Acute Otitis Media
      • 2.2.3.3 Bacterial Rhinosinusitis
      • 2.2.3.4 Diphtheria
      • 2.2.3.5 Pneumococcal Pneumonia
      • 2.2.3.6 Haemophilus Pneumonia
      • 2.2.3.7 Mycoplasma Pneumonia (Walking Pneumonia)
      • 2.2.3.8 Chlamydial Pneumonias and Psittacosis
      • 2.2.3.9 Health Care-Associated Pneumonia
      • 2.2.3.10 Pseudomonas Pneumonia
      • 2.2.3.11 Pertussis (Whooping Cough)
      • 2.2.3.12 Legionnaires Disease
    • 2.2.4 Tuberculosis - A Special Case
    • 2.2.5 Viral Infections
      • 2.2.5.1 The Common Cold
      • 2.2.5.2 Influenza
      • 2.2.5.3 Viral Pneumonia
      • 2.2.5.4 SARS and MERS
      • 2.2.5.5 Measles (Rubeola)
      • 2.2.5.6 Rubella (German Measles)
      • 2.2.5.7 Chickenpox and Shingles
    • 2.2.6 Fungal and Other Pathogens
      • 2.2.6.1 Histoplasmosis
      • 2.2.6.2 Coccidioidomycosis
      • 2.2.6.3 Blastomycosis
      • 2.2.6.4 Mucormycosis
      • 2.2.6.5 Aspergillosis
      • 2.2.6.6 Pneumocystis Pneumonia
      • 2.2.6.7 Cryptococcosis
  • 2.3 Diagnostics - A Changing Role
    • 2.3.1 Historical Practice
    • 2.3.2 Current Diagnostics
    • 2.3.3 The Multiplex Vector
    • 2.3.4 Future Diagnostics - The Question of When and Where
    • 2.3.5 Respiratory Infection Diagnostics - The Destination
    • 2.3.6 Diagnostics as Defensive Weapons

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1. Syndromic Multiplexing
    • 3.1.2 T.A.T
    • 3.1.3 Antimicrobial Resistance Movement
    • 3.1.4 Pandemic Mitigation
    • 3.1.5 An Aging at Risk Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 The Cost Curve
    • 3.2.2 Regulation and coverage
    • 3.2.3 Laissez Faire
  • 3.3 Instrumentation and Automation
    • 3.3.1 The Shrinking Multiplexing Machine
    • 3.3.2 Bioinformatics Networking and Anonymous Reporting
  • 3.4 Diagnostic Technology Development
    • 3.4.1 The Key Role of Time to Result
    • 3.4.2 Single Cell Genomics Changes the Picture
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 Pathogen Identification - A Projected Timetable of the Future

4. Respiratory Infection Diagnostics Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
      • Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
      • Qiagen Respiratory Panel with Coronavirus Receives CE Mark
      • Lumos Diagnostics Closes $15M Series A Funding
      • Fusion Genomics Wins $1M to Assess NGS-Based Respiratory Tract Infection Assay
      • Coronavirus Detection Test Development by Co-Diagnostics
      • Rapid Diagnostics Completes Asset Purchase of Enigma Diagnostics
      • Flu-Like Epidemic Could Kill 80 Mn Globally
      • Startup developing AI for TB detection
      • Nipah Virus a Global Threat
      • Novacyt S.A.: New Molecular Respiratory Panel Ready for US Market
      • New DRC Ebola cases confirmed as FDA OKs rapid test
      • CE Mark for Smartphone-based Diagnostic Test for Adult Respiratory Disease
      • Curetis Submits Lower Respiratory Tract Infection Test for FDA Clearance
      • New rapid test diagnoses pneumonia and other lower respiratory infections
      • Ontera Awarded Contract for Zika Genotyping Test
      • Two New Members Join Global Diagnostics Network
      • BARDA Funding Health Security Solutions

5. Profiles of Key Players

  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akkoni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Atlas Genetics
  • Aus Diagnostics
  • BD Diagnostics
  • Biocartis
  • BioFire Diagnostics
  • bioMérieux
  • Bio-Rad Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Co-Diagnostics
  • Cue Health
  • Curetis
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin
  • Expedeon
  • Fusion Genomics.
  • GenePOC Diagnostics
  • Genetic Signatures
  • GenMark Dx
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexigene
  • Luminex
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Oxford Nanopore
  • Panagene
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • T2 Biosystems
  • Thermo Fisher
  • Veradus Labs
  • Veramarx

6. The Global Market for Respiratory Infection Diagnostics

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Technology - Overview
    • 6.2.1 Table - Global Market by Technology
    • 6.2.2 Chart - Global Market by Technology - 2019/2024 Comparison
    • 6.2.3 Chart - Global Market by Technology - 2019
    • 6.2.4 Chart - Global Market by Technology -2024
    • 6.2.5 Chart - Global Market by Technology - Share by Year
  • 6.3 Global Market by Plex - Overview
    • 6.3.1 Table - Global Market by Plex
    • 6.3.2 Chart - Global Market by Plex - 2019/2024 Comparison
    • 6.3.3 Chart - Global Market by Plex - 2019
    • 6.3.4 Chart - Global Market by Plex -2024
    • 6.3.5 Chart - Global Market by Plex - Share by Year
  • 6.4 Global Market by Place - Overview
    • 6.4.1 Table - Global Market by Place
    • 6.4.2 Chart - Global Market by Place - 2019/2024 Comparison
    • 6.4.3 Chart - Global Market by Place - 2019
    • 6.4.4 Chart - Global Market by Place -2024
    • 6.4.5 Chart - Global Market by Place - Share by Year

7. Global Respiratory Infection Diagnostic Markets - By Technology

  • 7.1 Microbiology
    • 7.1.1 Table Microbiology - by Country
    • 7.1.2 Chart - Microbiology Growth
  • 7.2 PCR
    • 7.2.1 Table PCR - by Country
    • 7.2.2 Chart - PCR Growth
  • 7.3 NGS
    • 7.3.1 Table NGS - by Country
    • 7.3.2 Chart - NGS Growth
  • 7.4 Immunoassay
    • 7.4.1 Table Immunoassay - by Country
    • 7.4.2 Chart - Immunoassay Growth
  • 7.5 Other
    • 7.5.1 Table Other - by Country
    • 7.5.2 Chart - Other Growth

8. Global Respiratory Infection Diagnostic Markets - by Plex

  • 8.1 Single Plex
    • 8.1.1 Table Single Plex - by Country
    • 8.1.2 Chart - Single Plex Growth
  • 8.2 Duplex
    • 8.2.1 Table Duplex - by Country
    • 8.2.2 Chart - Duplex Growth
  • 8.3 Triplex
    • 8.3.1 Table Triplex - by Country
    • 8.3.2 Chart - Triplex Growth
  • 8.4 Multiplex Technology
    • 8.4.1 Table Multiplex - by Country
    • 8.4.2 Chart - Multiplex Growth

9. Global Respiratory Infection Diagnostic Markets - by Place

  • 9.1 Hospital Lab
    • 9.1.1 Table Hospital Lab - by Country
    • 9.1.2 Chart - Hospital Lab Growth
  • 9.2 Outpatient Lab
    • 9.2.1 Table Outpatient Lab - by Country
    • 9.2.2 Chart - Outpatient Lab Growth
  • 9.3 POC
    • 9.3.1 Table POC - by Country
    • 9.3.2 Chart - POC Growth
  • 9.4 Other Technology
    • 9.4.1 Table Other - by Country
    • 9.4.2 Chart - Other Growth

Appendices

  • I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule